Enanta Pharmaceuticals (ENTA) Interest & Investment Income (2012 - 2026)

Enanta Pharmaceuticals has reported Interest & Investment Income for 15 years, with the latest figure at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 9.08% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $8.9 million (down 24.65% YoY), and the FY2025 full-year result was $9.4 million, down 36.07% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $2.1 million, down from $2.4 million in the prior quarter.
• The five-year high for Interest & Investment Income was $4.7 million in Q3 2023, with the low at $255000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $2.4 million across 5 years, with a median of $2.3 million in 2025.
• Annual changes were most pronounced in 2023 — Interest & Investment Income jumped 883.72% — and 2025, when it tumbled 39.83%.
• Enanta Pharmaceuticals' Interest & Investment Income stood at $993000.0 in 2022, then soared by 332.83% to $4.3 million in 2023, then sank by 34.88% to $2.8 million in 2024, then decreased by 13.47% to $2.4 million in 2025, then fell by 13.96% to $2.1 million in 2026.
• The last three Interest & Investment Income figures came in at $2.1 million (Q1 2026), $2.4 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.